Prof. IsabellaCavalcanti – Cancer Science – Best Researcher Award

Posted on by Pencis

Prof. IsabellaCavalcanti - Cancer Science - Best Researcher Award

Federal University of Pernambuco (UFPE) - Brazil

Author Profile

Google Scholar 

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Isabella Macário Ferro Cavalcanti began her academic journey by graduating in Biomedicine from the Federal University of Pernambuco (UFPE). Following this, she pursued a master's degree in Therapeutic Innovation at UFPE, delving into advanced studies in the field. She then proceeded to earn her doctorate in Biotechnology, further refining her expertise in biological sciences.

PROFESSIONAL ENDEAVORS

Dr. Cavalcanti's professional career has been marked by significant accomplishments. She specializes in Clinical Microbiology, obtaining further specialization at the University of Pernambuco (UPE). Currently, she serves as a professor at UFPE, where she contributes to the education and training of future professionals in the field. Her involvement extends to leadership roles within various post-graduate programs, emphasizing her dedication to academic advancement.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Dr. Cavalcanti's research endeavors are diverse and impactful. As the Head and Researcher of Clinical Microbiology at the Laboratory of Immunopathology Keizo Asami at UFPE (LIKA/UFPE), she spearheads investigations into drug delivery systems and their biological activities. Her research group, MicroNAT, focuses on innovative approaches to combat multi-drug-resistant bacteria and biofilm formation. Through her work, she seeks to advance pharmaceutical nanotechnology and fundamental microbiological understanding.

IMPACT AND INFLUENCE

Isabella Macário Ferro Cavalcanti's contributions have had a profound impact on the fields of pharmaceutical nanotechnology and microbiology. Her research findings contribute to the development of novel therapeutic strategies and the understanding of microbial resistance mechanisms. As a respected member of the Brazilian Society of Microbiology and various scientific committees, her expertise is recognized nationally and internationally.

ACADEMIC CITATIONS

Dr. Cavalcanti's work has garnered significant attention within the academic community, reflected in numerous citations of her research publications. Her contributions to scientific literature serve as a foundation for further exploration and innovation in the fields of biotechnology, microbiology, and drug delivery.

LEGACY AND FUTURE CONTRIBUTIONS

With a strong foundation in academia and research, Dr. Cavalcanti's legacy is marked by her dedication to advancing knowledge and addressing critical healthcare challenges. Her leadership in research groups and academic programs ensures the continued development of future scientists and the pursuit of innovative solutions to complex biomedical problems. As she continues her career, her contributions are poised to further shape the landscape of biomedicine and microbiology, leaving a lasting legacy of excellence and innovation.

NOTABLE PUBLICATIONS

Zein nanoparticles containing ceftazidime and tobramycin: antibacterial activity against Gram-negative bacteria. 2024

Proteomic characterization and biological activities of the mucus produced by the zoanthid Palythoa caribaeorum (Duchassaing & Michelotti, 1860) 2023

Efficacy and non-toxicity of ciclopirox olamine-loaded liposomes against Cryptococcus neoformans clinical isolates. 2023

Gram-negative bacilli carrying mcr gene in Brazil: a pathogen on the rise. 2023

Antibiotic resistance profiles on pathogenic bacteria in the Brazilian environments. 2023

Prof Dr. Rommel MarioRodriguez Burbano – Oncology and Precision Medicine – Best Researcher Award

Posted on by Pencis

Prof Dr. Rommel MarioRodriguez Burbano - Oncology and Precision Medicine - Best Researcher Award

Ophir Loyola Hospital - Brazil

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Rommel Mario Rodríguez Burbano began his academic journey by earning a degree in Biomedicine from the Federal University of Pará in 1989. He then pursued further education, completing his Master's (1993) and Ph.D. (1998) in Biological Sciences (Genetics) from the Faculty of Medicine of Ribeirão Preto, University of São Paulo.

PROFESSIONAL ENDEAVORS

After completing his formal education, Rommel embarked on a diverse and impactful professional career. He conducted post-doctoral research in Morphology at the Discipline of Genetics, Escola Paulista de Medicina, Federal University of São Paulo in 2005. Currently, he holds the prestigious position of Full Professor at the Federal University of Pará.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Rommel Mario Rodríguez Burbano's contributions to academia are significant and multifaceted. His research primarily focuses on Human Genetics, Cell Biology, and Oncology. Throughout his career, he has demonstrated a keen interest in understanding molecular mechanisms underlying diseases, particularly cancer.

IMPACT AND INFLUENCE

Rommel's work has had a profound impact on the scientific community. His extensive publication record, comprising 296 scientific articles in specialized journals, one book, and seven book chapters, reflects his dedication to advancing knowledge in his field.

ACADEMIC CITATIONS

Rommel's research output has garnered considerable attention, as evidenced by his numerous academic citations. His work is widely recognized and cited by peers, contributing significantly to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS

As a mentor and supervisor, Rommel has played a pivotal role in shaping the next generation of scientists. He has supervised a total of 44 master's theses, 41 doctoral theses, and mentored five postdoctoral fellows. His legacy extends beyond his own research contributions, influencing the work of numerous scholars who have benefited from his guidance and expertise.

HIGHLIGHTS

Rommel currently serves as the Coordinator of the Molecular Biology Laboratory at Hospital Ophir Loyola in Belém, Pará, indicating his leadership in translational research.He holds the Process and Molecular Biomarker patent, demonstrating his innovative approach to addressing scientific challenges.Rommel's involvement in editorial boards of 12 scientific journals and his role as a reviewer for numerous scientific publications underscore his commitment to peer-reviewed research and quality scholarship.

NOTABLE PUBLICATIONS

Homocystein, Vitamin B12 and Folic Acid as Screening Biomarkers in Early Diagnosis and Gastric Cancer Monitoring.  2024

Efficacy and Safety of Anti-CD38 Monoclonal Antibodies in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Randomized Clinical Trials. 2024

Molecular Profile of Variants Potentially Associated with Severe Forms of COVID-19 in Amazonian Indigenous Populations. 2024 (1)

Efficacy and safety of Zolbetuximab plus chemotherapy for advanced CLDN18.2-positive gastric or gastro-oesophageal adenocarcinoma: a meta-analysis of randomized clinical trials. 2024

PARP1 Characterization as a Potential Biomarker for BCR::ABL1 p190+ Acute Lymphoblastic Leukemia. 2023

 

 

Prof Dr. ClausGarbe – Oncology Management and Prevention – Lifetime achievement Award

Posted on by Pencis

Prof Dr. ClausGarbe - Oncology Management and Prevention - Lifetime achievement Award

University of Tuebingen - Germany

AUTHOR PROFILE

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Professor Claus Garbe embarked on his academic journey by obtaining his MD from the Free University of Berlin in 1983. Following this, he pursued board certification in Dermatology and Venereology in 1987. His early academic pursuits laid the foundation for his subsequent groundbreaking work in dermatology and oncology.

PROFESSIONAL ENDEAVORS:

In 1990, Professor Garbe achieved his habilitation, akin to a PhD equivalent, with a focus on the biology of melanoma cells. This marked a significant milestone in his academic career, demonstrating his commitment to advancing the understanding of melanoma, a deadly form of skin cancer. In 1995, he transitioned to Eberhard Karls University, Tuebingen, where he assumed the role of University Professor of Dermatology and Head of the Division of Dermatooncology. This move expanded his scope of influence and provided a platform for furthering his research and clinical endeavors.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY MANAGEMENT AND PREVENTION

Professor Garbe's contributions to the field of dermatology and oncology are extensive and profound. His principal research interests encompass the biology and genetics of melanoma and keratinocyte skin cancers, therapeutic trials in skin diseases, epidemiologic studies, and dermato-histopathology. Through his pioneering research, he has elucidated crucial mechanisms underlying skin cancer development and progression, paving the way for innovative therapeutic approaches and preventive strategies.

IMPACT AND INFLUENCE:

Professor Garbe's impact on the field of dermatologic oncology is unparalleled. His leadership roles in numerous multicenter clinical trials since 1989 have facilitated the translation of research findings into clinical practice, ultimately improving patient outcomes. Moreover, his presidency of the European Association of Dermatologic Oncology (EADO) underscores his influence on a global scale, driving collaboration and innovation in the fight against skin cancer.

ACADEMIC CITATIONS:

With over 800 articles and 17 textbooks to his name, Professor Garbe's scholarly output is prolific. His impressive H-index of 116 points reflects the significant impact of his work within the scientific community. His research findings have been cited extensively, highlighting their relevance and contribution to advancing knowledge in dermatology and oncology.

LEGACY AND FUTURE CONTRIBUTIONS:

Professor Garbe's legacy is characterized by his unwavering dedication to advancing the field of dermatologic oncology. His contributions have not only expanded our understanding of skin cancer but have also shaped clinical practice and guidelines. As he continues to spearhead research efforts and mentor the next generation of scientists and clinicians, his legacy is poised to endure, leaving an indelible mark on the field for years to come.

NOTABLE PUBLICATIONS

Sentinel lymph node biopsy is unreliable in predicting melanoma mortality for both younger and older patients. 2024 (2)

Sentinel lymph node biopsy for lentigo maligna melanoma under local anaesthesia. 2024 (3)

Epidemiology of Keratinocyte Skin Cancer with a Focus on Cutaneous Squamous Cell Carcinoma. 2024 (1)

European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment–Update 2023. 2023 (6)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial. 2023 (2)

Dr. Sumaira Mubarik – Cancer Science – Best Researcher Award

Posted on by Pencis

Dr. Sumaira Mubarik - Cancer Science - Best Researcher Award

University of Groningen - Netherlands

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS:

Summaira Mubarik embarked on her academic journey with a strong foundation in mathematics, statistics, and computer science. She pursued her Bachelor of Science degree from Punjab University, Pakistan, specializing in Mathematics, Statistics, and Computer Science, which laid the groundwork for her future academic pursuits. Following this, she completed her FSc in Mathematics, Statistics, and Computer Science from BISE, Rawalpindi, Pakistan, further honing her analytical skills and preparing for advanced studies.

PROFESSIONAL ENDEAVORS:

Building upon her educational background, Mubarik pursued higher studies in statistics, earning her Master of Science degree from Arid Agriculture University Rawalpindi, Pakistan, in 2009. Subsequently, she completed her M.Phil, specializing in Statistics, from the same institution in 2012, where she conducted research on Quantile Regression Analysis of Blood Pressure levels for different factors of Adults under the supervision of Dr. Abdush Shakoor. These endeavors marked her entry into the realm of statistical research and analysis.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER SCIENCE

Mubarik's academic journey reached new heights when she pursued her PhD in Statistics at Wuhan University, China, from 2019 to 2021. Under the supervision of Prof. Chuanhua Yu, she delved into the domain of stochastic modeling and prediction of breast cancer risk transitions using the age-period-cohort framework. Her research not only showcased her expertise in applied statistics but also demonstrated a deep commitment to addressing critical issues in biostatistics and epidemiology.

IMPACT AND INFLUENCE:

Throughout her academic career, Mubarik has made significant contributions to the field of statistics, particularly in applied statistics, biostatistics, and disease modeling. Her research endeavors have the potential to impact public health policies and interventions aimed at mitigating the risk of breast cancer. Additionally, her work in stochastic mortality models and survival analysis holds promise for improving our understanding of disease progression and mortality patterns.

ACADEMIC CITATIONS:

Mubarik's research output has garnered attention and recognition within the academic community, as evidenced by her receipt of prestigious scholarships and awards. She was awarded the "Excellent International Student Award" from the Ministry of Education, China, in 2020, along with the Wuhan University Outstanding International Students Scholarship in 2020 and 2021 for her exceptional academic achievements.

LEGACY AND FUTURE CONTRIBUTIONS:

As an Assistant Professor at the University of Groningen, Netherlands, Mubarik continues to pursue her passion for statistics and research. Her expertise in pharma data science and statistics equips her to contribute significantly to the advancement of statistical methodologies in pharmaceutical research and healthcare. With a strong foundation in applied statistics and a focus on epidemiological modeling, Mubarik's future contributions hold the potential to shape the landscape of public health research and policy.

NOTABLE PUBLICATIONS

Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990–2019: A comparable study of key nations with emerging economies. 2024 (1)

Global age-sex-specific mortality, life expectancy, and population estimates in 204 countries and territories and 811 subnational locations, 1950–2021, and the impact of the COVID-19 pandemic: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 2024 (5)

Global fertility in 204 countries and territories, 1950–2021, with forecasts to 2100: a comprehensive demographic analysis for the Global Burden of Disease Study 2021. 2024 (1)

Global, regional, and national burden of disorders affecting the nervous system, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. 2024 (4)

Temporal patterns of cancer burden in Asia, 1990–2019: a systematic examination for the Global Burden of Disease 2019 study 2024

Prof. R. StephanieHuang – Oncology and Precision Medicine – Best Researcher Award 

Posted on by Pencis

Prof. R. StephanieHuang - Oncology and Precision Medicine - Best Researcher Award 

University Of Minnesota - Minneapolis, MN - United States

Author Profile

Scopus 

Orcid

Early Academic Pursuits

Dr. Rong Stephanie Huang's academic journey began with her pursuit of pharmacology at the University of Minnesota, where she eventually earned the title of Distinguished McKnight University Professor. Her early academic pursuits laid the foundation for her distinguished career in the field.

Professional Endeavors

Throughout her career, Dr. Huang has held prestigious academic appointments, including her current position in the Department of Experimental and Clinical Pharmacology at the University of Minnesota. Her commitment to advancing pharmacology is evident in her leadership roles and contributions to various professional societies.

Contributions and Research Focus on Oncology and Precision Medicine

Dr. Huang's research primarily focuses on personalized and precision medicine, particularly in oncology. Her work aims to tailor treatments to individual patients by understanding the genetic and molecular mechanisms underlying cancer progression. This research has significant implications for improving patient outcomes in cancer treatment.

Impact and Influence

As a respected leader in pharmacology, Dr. Huang's influence extends beyond her research. Her leadership roles in organizations such as the International Pharmaceutical Federation (FIP) highlight her dedication to advancing the field on a global scale. Her contributions have shaped the landscape of personalized medicine and oncology research.

Academic Citations

Dr. Huang's research has garnered substantial attention within the academic community, evidenced by the numerous citations her work has received. Her findings have contributed to advancing knowledge in pharmacology, particularly in the realm of personalized medicine and cancer research.

Legacy and Future Contributions

Dr. Huang's legacy is characterized by her significant contributions to pharmacology and personalized medicine. Her ongoing leadership roles and mentorship efforts ensure that her impact will endure for future generations of pharmacologists. As she continues her research and advocacy, Dr. Huang will undoubtedly leave a lasting legacy in the field.

Notable Publications

Computational Modeling to Identify Drugs Targeting Metastatic Castration-Resistant Prostate Cancer Characterized by Heightened Glycolysis.

Integration of Computational Pipeline to Streamline Efficacious Drug Nomination and Biomarker Discovery in Glioblastoma.

Integration of pan-cancer cell line and single-cell transcriptomic profiles enables inference of therapeutic vulnerabilities in heterogeneous tumors.

A review of computational methods for predicting cancer drug response at the single-cell level through integration with bulk RNAseq data.

 

 

 

Prof Dr. Nives Pećina-Šlaus – Cancer Genetics – Best Researcher Award

Posted on by Pencis

Prof Dr. Nives Pećina-Šlaus - Cancer Genetics - Best Researcher Award

Department of Biology School of Medicine University of Zagreb - Croatia

AUTHOR PROFILE 

Google Scholar

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Nives Pecina-Slaus embarked on her academic journey at the University of Zagreb, where she earned her Bachelor's and Master's degrees in Biology in 1990 and 1992, respectively. Her scholarly pursuits culminated in a Ph.D. in the field of molecular oncology from the Medical School at the University of Zagreb in 1998. During her education, she underwent training at prestigious institutions including the Cold Spring Harbor Laboratory in New York and Georgetown University in Washington DC, USA.

PROFESSIONAL ENDEAVORS

Pecina-Slaus's professional career is distinguished by her role as a tenured professor at the Department of Biology and Head of the Laboratory of Neuro-oncology at the Croatian Institute for Brain Research within the School of Medicine at the University of Zagreb. She has served as the principal investigator on seven scientific projects, demonstrating her leadership in the field. Moreover, her research has yielded significant contributions, with over 100 publications to her credit, including scientific papers, book chapters, and a book. Her primary research interests encompass cancer genetics, the Wnt signaling pathway, epithelial to mesenchymal transition, brain tumorigenesis, tumor suppressor genes, and oncogenes.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Pecina-Slaus's work has contributed extensively to our understanding of neuro-oncology and related fields. Her research has shed light on crucial mechanisms underlying cancer development and progression, particularly in the context of brain tumors. Through her numerous publications, she has disseminated valuable insights into cancer genetics, signaling pathways, and tumor microenvironment dynamics. Her expertise extends to mentorship, where she has guided numerous students in their theses.

IMPACT AND INFLUENCE

Pecina-Slaus's contributions have garnered widespread recognition in the scientific community, as evidenced by her invitations to speak at 25 meetings. Furthermore, her work has had a substantial impact on the academic community, as reflected in her impressive citation metrics. With over 2600 citations on Google Scholar and notable indices on Scopus and Web of Science, she has established herself as a respected authority in her field.

ACADEMIC LEGACY AND FUTURE CONTRIBUTIONS

Pecina-Slaus's legacy is marked by her prolific research output, mentorship of students, and editorial roles in esteemed scientific journals. Her dedication to advancing knowledge in neuro-oncology and related disciplines has earned her numerous awards and accolades, including recognition from the Croatian Medical Association and the Academy of Medical Sciences. Moving forward, she is poised to continue making significant contributions to the field through her research, teaching, and editorial activities, further solidifying her position as a leader in neuro-oncology research.

NOTABLE PUBLICATIONS

Glioma Stem Cells—Features for New Therapy Design. 2024

Genetics in ophthalmology: molecular blueprints of retinoblastoma. 2023 (3)

Wnt Signaling Inhibitors and Their Promising Role in Tumor Treatment. 2023 (6)

Different Approaches to Study Molecular Blueprint and Biological Behavior of Brain Tumors: Editorial to the Special Issue “Advances in Molecular Genetics of Brain Tumors”. 2023

Bilateral Meningioma: A Case Report and Review of the Literature. 2022 (2)

 

 

Prof Dr. Zsuzsanna Suba – Cancer Genetics – Distinguished Cancer Treatment Innovation Award

Posted on by Pencis

Prof Dr. Zsuzsanna Suba - Cancer Genetics - Distinguished Cancer Treatment Innovation Award

National Institute of Oncology, Budapest - Hungary

AUTHOR PROFILE

Orcid

EARLY ACADEMIC PURSUITS

Prof. Dr. Zsuzsanna Suba began her academic journey at Semmelweis University in Budapest, where she earned both MD and PhD degrees. During this time, she also obtained postdoctoral board certification in pathology, laying the foundation for her expertise in cancer research.

PROFESSIONAL ENDEAVORS

After completing her postdoctoral certification, Suba delved into cancer research, initially focusing on the effects of chemotherapeutic agents on cell cultures and experimental animals. Later, she expanded her expertise by gaining scientific graduations in oral pathology and habilitation at the Institute of Oral and Maxillofacial Surgery, Semmelweis University, as well as a certification in oral pathology from the University of Sheffield.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Suba's research has been multifaceted, covering various aspects of cancer development and therapy response. She led a working group that investigated the osseointegration of biomaterials in oral and periodontal tissues and explored metabolic and hormonal aspects of oral cancer. Notably, her research identified insulin resistance and estrogen deficiency as risk factors for oral cancer.At the National Institute of Oncology in Budapest, Suba delved into the correlations among hormonal imbalance, metabolic disorders, and genomic instability in female breast cancer patients.

IMPACT AND INFLUENCE

Suba's work has significantly contributed to our understanding of cancer development and treatment response, particularly in oral and breast cancer. Her identification of novel risk factors and exploration of hormonal and metabolic influences have informed both clinical practice and further research in the field.

ACADEMIC CITATIONS

Suba's contributions to cancer research have garnered recognition and citations within the academic community, solidifying her reputation as an expert in clinical cancer genetics and pathology.

LEGACY AND FUTURE CONTRIBUTIONS

As a professor emeritus, Suba continues to shape the future of cancer research, advocating for new strategies that prioritize DNA stabilization in cancer cases. Her emphasis on supportive cancer care underscores the importance of innovative approaches to enhance patient outcomes and quality of life.

NOTABLE PUBLICATIONS

DNA Damage Responses in Tumors Are Not Proliferative Stimuli, but Rather They Are DNA Repair Actions Requiring Supportive Medical Care. 2024

Compensatory Estrogen Signal Is Capable of DNA Repair in Antiestrogen-Responsive Cancer Cells via Activating Mutations. 2020 (7)

 

Prof. Vincenzo Quagliariello – Cardio-oncology – Best Researcher Award

Posted on by Pencis

Prof. Vincenzo Quagliariello - Cardio-oncology - Best Researcher Award

Division of Cardiology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale - Italy

AUTHOR PROFILE

Scopus

Orcid

EARLY ACADEMIC PURSUITS

Dr. Vincenzo Quagliariello embarked on his academic journey by specializing in Clinical Biochemistry and Clinical Pathology at the University of Campania Luigi Vanvitelli. This laid the groundwork for his future endeavors in the medical field.

PROFESSIONAL ENDEAVORS

His professional journey saw him contribute significantly to the field of medical research. He held a fixed-term contract as a "Health Researcher DS6" at the prestigious Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Division of Cardiology, where he made notable contributions to the study of cardiology.

CONTRIBUTIONS AND RESEARCH FOCUS ON CARDIO-ONCOLOGY

Dr. Quagliariello's research focus spans various areas, including biochemistry, clinical pathology, and cardiology. Notably, he has participated as a speaker in numerous national and international congresses since 2011, showcasing his expertise and sharing valuable insights with the scientific community.

IMPACT AND INFLUENCE

His contributions to the field of medical research are underscored by his involvement in the development of innovative medical devices and pharmaceutical formulations aimed at enhancing the efficacy of cancer treatment. Dr. Quagliariello's work has the potential to positively impact patient care and outcomes.

ACADEMIC CITATIONS

Dr. Quagliariello's work has likely garnered attention within the academic community, potentially leading to citations in scholarly literature. His involvement in pioneering research projects and participation in congresses further solidify his standing in the scientific community.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Quagliariello's legacy lies in his dedication to advancing medical science, particularly in the fields of Cardio-oncology. His innovative patents and contributions to scientific literature lay the foundation for future breakthroughs in cancer treatment and cardiovascular medicine. As he continues his academic and professional journey, he is poised to make even greater contributions to the field, leaving a lasting impact on healthcare and patient outcomes.

NOTABLE PUBLICATIONS

The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients. 2024

Combination of Spirulina platensis, Ganoderma lucidum and Moringa oleifera Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology? 2022 (12)

The Multiple Effects of Vitamin D against Chronic Diseases: From Reduction of Lipid Peroxidation to Updated Evidence from Clinical Studies. 2022 (24)

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin. 2021 (199)

Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives. 2021 (40)

 

 

 

 

 

 

 

 

 

Prof Dr. TatianaTilli – Oncology and Precision Medicine – Women Researcher Award

Posted on by Pencis

Prof Dr. TatianaTilli - Oncology and Precision Medicine - Women Researcher Award

Oswaldo Cruz Foundation - Brazil

AUTHOR PROFILE

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Tatiana Martins Tilli pursued her Doctorate in Medicine from the Instituto Nacional de Câncer (INCA) in Rio De Janeiro, Brazil. Her research focused on the functional characterization of splicing variant isoforms of osteopontin in ovarian and prostate carcinomas. This research was conducted under the guidance of Dr. Etel Rodrigues Pereira Gimba and Dr. Akeila Bellahcène at the Université de Liège during her Sandwich Doctorate. The study highlighted the significance of osteopontin as a molecular marker in ovarian and prostate cancers, emphasizing the role of splicing isoforms.Prior to her doctorate, Dr. Tilli completed her Master's in Medicine at INCA. Her research focused on autoantibodies against osteopontin as potential serum markers in neoplasms. This research further underscored the importance of osteopontin as a molecular marker in oncology and provided insights into its immunological aspects.

PROFESSIONAL ENDEAVORS

After completing her doctorate, Dr. Tilli pursued her postdoctoral research at the University of Alberta in Edmonton, Canada. Her postdoctoral work encompassed areas such as Systems Biology, Cellular Biology, and Molecular Biophysics. This period allowed her to expand her research expertise and collaborate with international experts in her field.Currently, Dr. Tilli serves as a public servant in a full-time and exclusive capacity, dedicating 40 hours weekly as a researcher. Her role involves conducting research in the domain of human health, building on her extensive academic background and professional experience.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Tilli's research has primarily revolved around osteopontin, a molecule of significant interest in oncology. Her studies have explored the functional characterization of splicing variant isoforms of osteopontin and the potential of autoantibodies against osteopontin as serum markers in neoplasms. These research endeavors have contributed significantly to the understanding of molecular markers in ovarian and prostate cancers.

IMPACT AND INFLUENCE

Dr. Tilli's work has had a substantial impact on the field of oncology, particularly in the identification and characterization of molecular markers in ovarian and prostate cancers. Her research findings have been influential in shaping the current understanding of osteopontin's role in cancer biology and its potential applications in diagnostic and therapeutic strategies.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Tatiana Martins Tilli has established herself as a leading researcher in the field of oncology, with a focus on molecular markers, particularly osteopontin. Her legacy lies in her significant contributions to understanding the role of osteopontin in ovarian and prostate cancers.In the future, Dr. Tilli is expected to continue her groundbreaking research, further exploring the potential applications of osteopontin and its variants in cancer diagnosis, prognosis, and targeted therapy. Her continued dedication to advancing the field of oncology promises to yield further impactful contributions to human health.

NOTABLE PUBLICATIONS

Unlocking Overexpressed Membrane Proteins to Guide Breast Cancer Precision Medicine. 2024

Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis. 2024

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. 2022

Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. 2021

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. 2021

Dr. VICTOR NAVA – Pathology – Best Researcher Award

Posted on by Pencis

Dr. VICTOR NAVA - Pathology - Best Researcher Award

GEORGE WASHINGTON UNIVERSITY - United States

AUTHOR PROFILE

Google Scholar
Orcid
Scopus

EARLY ACADEMIC PURSUITS

Victor Eduardo Nava began his academic journey at the Central University of Venezuela, where he pursued his Medical Degree from 1983 to 1990. This foundational education provided him with the essential knowledge and skills in medicine.After obtaining his M.D., Victor Eduardo Nava furthered his academic pursuits at Tulane University's Graduate School. Here, he earned a Master of Science degree from the Department of Parasitology in 1993.Continuing his academic journey, Nava pursued a Ph.D. at Johns Hopkins University's School of Public Health. Under the guidance of his advisor, J. Marie Hardwick, Ph.D., he specialized in Molecular Microbiology and Immunology, completing his doctoral studies in 1998.

PROFESSIONAL ENDEAVORS

Victor Eduardo Nava undertook his PGY1 Residency in Anatomic Pathology/Clinical Pathology at Georgetown University Hospital under the mentorship of Norio Azumi, M.D., Ph.D., in 2001-2002.From 2002 to 2004, Nava continued his residency in Anatomic Pathology at the National Institutes of Health/National Cancer Institute's Laboratory of Pathology. His mentors during this period were Elaine Jaffe, M.D., and Maria Merino, M.D. Nava completed a fellowship in Hematopathology at Georgetown University Hospital from 2004 to 2006, mentored by Metin Ozdemirli, M.D., Ph.D.

CONTRIBUTIONS AND RESEARCH FOCUS ON PATHOLOGY

Throughout his career, Victor Eduardo Nava has made significant contributions to the field of Pathology, particularly in Hematopathology and Surgical Pathology. His research has focused on molecular microbiology, immunology, and the pathology of hematological disorders.

IMPACT AND INFLUENCE

Dr. Nava's work has had a profound impact on the understanding and diagnosis of hematological diseases. His research and clinical expertise have influenced medical practices and contributed to advancements in the field of pathology.

ACADEMIC CITES

Victor Eduardo Nava has been recognized for his scholarly contributions with numerous citations in academic journals and publications. His research papers and studies have been referenced by peers and professionals in the field, highlighting the significance and relevance of his work.

LEGACY AND FUTURE CONTRIBUTIONS

As the Blood Bank Director and Attending Hematopathologist/Surgical Pathologist at the Veterans Affairs Medical Center in Washington, DC, and Assistant Professor at George Washington University since 2007, Dr. Nava continues to make a lasting impact. His dedication to teaching, research, and patient care ensures that his legacy will endure, with future contributions expected to further advance the field of Pathology.

NOTABLE PUBLICATIONS

Ductal Adenocarcinoma of the Prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing. 2024

Myelodysplastic Neoplasms (MDS): A Narrative Review from the Era of Precision Medicine. 2024

Novel Therapeutics for Malaria. 2023

Refractory Splenic Marginal Zone Lymphoma Responsive to Combination Venetoclax and Bortezomib (Velcade) (V<sup>2</sup>) Therapy. 2022

Concurrent Waldenstrom’s Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation. 2022